Effects on apoptosis, cell cycle and transformation, and comparative aspects of EBV with other known DNA tumor viruses

Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis

Volumn , Issue , 2007, Pages 514-539

  Klein, George ^a   Ernberg, Ingemar ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650663196     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545313.030     Document Type: Chapter

References (154)

1. Ambinder, R. F., Shah, W. A., Rawlins, D. R., Hayward, G. S., and Hayward, S. D.(1990). De?nition of the sequence requirements for binding of the EBNA-1 protein to its palindromictarget sites in Epstein-Barr virus DNA. J. Virol., 64, 2369-2379.
2. Aman, P., Rowe, M., Kai, C. et al. (1990). Effect of the EBNA-2 gene on the surface antigen phenotype of transfected EBV-negative B-lymphoma lines. Int. J. Cancer, 45, 77-82.
3. Andersson-Anvret, M., Klein, G., Forsby, N., and Henle, W. (1978). The association between undifferentiated nasopharyngeal carcinoma and Epstein-Barr virus shown by correlated nucleic acid hybridization and histopathological studies. IARC Sci. Publ., 20, 347-357.
4. Amini, R. M., Enblad, G., Gustavsson, A. et al. (2000). Treatmentout-come in patients younger than 60 years with advanced stages (IIB-IV)of Hodgkin's disease: The Swedish National Health Care Programme experience. Eur. J. Haematol., 65, 379-389.
5. Axdorph, U., Porwit-MacDonald, A., Sjoberg, J. et al. (1999). Epstein-Barr virus expression in Hodgkin's disease in relation to patientcharacteristics, serum factors and blood lymphocyte function. Br. J. Cancer, 81, 1182-1187.
6. Baichwal, V. R., Hammerschmidt, W., and Sugden, B. (1989). Char-acterization of the BNLF-1 oncogene of Epstein-Barr virus. Curr. Top. Microbiol. Immunol., 144, 233-239.
7. Bittner, J. J. (1936). Some possible effects of nursing on the mam-mary tumor incidence in mice. Science, 84, 162-168.
8. Bodescot, M. and Perricaudet, M.(1986). Epstein-Barr virusmRNAs produced by alternative splicing. Nucl. Acids Res., 14, 7103-7114.
9. Bodescot, M., Perricaudet, M., and Farrell, P. J. (1987). A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J. Virol., 61, 3424-3430.
10. Bornkamm, G. W. and Hammerschmidt, W. (2001). Molecular virol-ogy of Epstein-Barr virus. Phil. Trans. R. Soc. Lond. B Biol. Sci., 356, 437-459.
11. Burkhardt, A. L., Bolen, J. B., Kieff, E., and Longnecker, R. (1992). An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases. J. Virol., 66, 5161-5167.
12. Caldwell, R. G., Brown, R. C., and Longnecker, R. (2000). Epstein-Barrvirus LMP2A-inducedB-cellsurvivalintwouniqueclasses of EmuLMP2A transgenic mice. J. Virol., 74, 1101-1113.
13. Chen, F., Hu, L. F., Ernberg, I., Klein, G., and Winberg, G. (1995a). A subpopulation of normal B cells latenly infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J. Virol., 69, 3752-3758.
14. Chen, F., Zou, J. Z., di Renzo, L. etal.(1995b). Asubpopulationofnor-mal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J. Virol., 69, 3752-3758.
15. Chen, F., Chen, L., Lindwall, C., Xu, D., and Ernberg, I. (2004). Epstein-Barr virus latent membrane 2A (LMP2A) down-regulates telomerase reverse transcriptase (hTERT) in epithe-lial cell lines. Int. J. Cancer.
16. Chung, P. J., Chang, Y. S., Liang, C. L., and Meng, C. L. (2002). Neg-ative regulation of Epstein-Barr virus latent membrane pro-tein 1-mediated functions by the bone morphogenetic pro-tein receptor IA-binding protein, BRAM1. J. Biol. Chem., 277, 39850-39857.
17. Cohen, J. I., Wang, F., Mannick, J., and Kieff, E. (1989). Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl Acad Sci. USA., 86, 9558-9562.
18. Contreras-Salazar, B., Klein, G., and Masucci, M. G. (1989). Host cell-dependent regulation of growth transformation-associated Epstein-Barr virus antigens in somatic cell hybrids. J. Virol., 63, 2768-2772.
19. Damania, B., Choi, J. K., and Jung, J. U. (2000). Signaling activities of gammaherpesvirus membrane proteins. J. Virol., 74, 1593-1601.
20. Devergne, O., Hatzivassiliou, E., Izumi, K. M. et al. (1996). Associa-tion of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: Role in NF-kappaB activation. Mol. Cell Biol., 16, 7098-7108.
21. Dillner, J., Kallin, B., Ehlin-Henriksson, B., Timar, L., and Klein, G. (1985). Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA. Int. J. Cancer, 35, 359-366.
22. Dillner, J., Kallin, B., Alexander, H. et al. (1986a). An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: Preferential expression in lymphoblastoid cell lines. Proc. Natl Acad. Sci. USA, 83, 6641-6645.
23. Dillner, J., Kallin, B., Ehlin-Henriksson, B. et al. (1986b). The Epstein-Barr virus determined nuclear antigen is composed of at least three different antigens. Int. J. Cancer, 37, 195-200.
24. Dirmeier, U., Neuhierl, B., Kilger, E., Reisbach, G., Sandberg, M. L., and Hammerschmidt, W. (2003). Latent membrane protein 1 is critical for ef?cient growth transformation of human B cells by Epstein-Barr virus. Cancer Res., 63, 2982-2989.
25. Drouet, E., Brousset, P., Fares, F. etal.(1999). High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease. J. Med. Virol., 57, 383-389.
26. Dukers, D. F., Jaspars, L. H., Vos, W. et al. (2000). Quantita-tive immunohistochemical analysis of cytokine pro?les in Epstein-Barr virus-positive and-negative cases of Hodgkin's disease. J. Pathol., 190, 143-149.
27. Dykstra, M. L., Longnecker, R., and Pierce, S. K. (2001). Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR. Immunity, 14, 57-67.
28. Eliopoulos, A. G. and Young, L. S. (2001). LMP1 structure and signal transduction. Semin. Cancer Biol. Rev., 11, 435-444.
29. Eliopoulos, A. G., Dawson, C. W., Mosialos, G. et al. (1996). CD40-induced growth inhibition in epithelial cells is mim-icked by Epstein-Barr virus-encoded LMP1: Involvement of TRAF3 as a common mediator. Oncogene, 13, 2243-2254.
30. Eliopoulos, A. G., Stack, M., Dawson, C. W. et al. (1997). Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene, 14, 2899-2916.
31. Ernberg, I., Kallin, B., Dillner, J. et al. (1986). Lymphoblastoid cell lines and Burkitt-lymphoma-derived cell lines differ in the expression of a second Epstein-Barr virus encoded nuclear antigen. Int. J. Cancer, 38, 729-737.
32. Enblad, G., Sundstrom, C., and Glimelius, B. (1993). In?ltration of eosinophils in Hodgkin's disease involved lymph nodes pre-dicts prognosis. Hematol. Oncol., 11, 187-193.
33. Fahraeus, R., Rymo, L., Rhim, J. S., and Klein, G. (1990). Morpho-logical transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature, 345, 447-449.
34. Foulds, L. (1958). The natural history of cancer. J. Chronic Dis., 8, 2-37.
35. Friborg, J., Kong, W., Hottiger, M., and Nabel, G. (1999). P53 inhibi-tion by the LANA protein of KSHV protects against cell death. Nature, 402, 889-894.
36. Fruehling, S. and Longnecker, R. (1997). The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology, 235, 241-251.
37. Fruehling, S., Swart, R., Dolwick, K. M., Kremmer, E., and Longnecker, R. (1998). Tyrosine 112 of latent membrane pro-tein 2A is essential for protein tyrosine kinase loading and reg-ulation of Epstein-Barr virus latency. J. Virol., 72, 7796-7806.
38. Furth, J., Buffett, R. F., Barasiewicz-Rodriguez, M., and Upton, A. C. (1956). Characterofagentinducingleukemiainnewbornmice. Proc. Soc. Exp. Biol. Med., 93, 165-172.
39. Gallo, R. C., Kalyanaraman, V. S., Sarngadharan, M. G. et al. (1983). Association of the human type-C retrovirus with a subset of adult T-cell cancers. Cancer Res., 42, 3892-3899.
40. Geser, A. D., De The, G., Lenoir, G. et al. (1982). Final case report-ing from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. Int. J. Cancer, 29, 397-400.
41. Gires, O., Zimber-Strobl, U., Gonnella, R. et al. (1997). Latent mem-brane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J., 16, 6131-6140.
42. Gires, O., Kohlhuber, F., Kilger, E. et al. (1999). Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and acti-vates STAT proteins. EMBO J., 18, 3064-3073.
43. Glaser, S. L., Lin, R. J., Stewart, S. L. et al. (1997). Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data. Int. J. Cancer, 70, 375-382.
44. Gratama, J. W., Oosterveer, M. A. P., Zwaan, F. E., Lepoutre, J., Klein, G., and Ernberg, I. (1988). Eradication of Epstein-Barr virus by allogeneic bone marrow transplanation: Implications for sites of viral latency. Proc. Natl Acad. Sci. USA, 85, 8693-8696.
45. Gross, L. (1951). Spontaneous leukemia developing in C3H mice following inoculation in infancy with AK leukemic extracts of AK embryos. Proc. Soc. Exp. Biol. Med., 76, 27-32.
46. Hatzivassiliou, E. and Mosialos, G. (2002). Cellular signaling path-ways engaged by the Epstein-Barr virus transforming protein LMP1. Front Biosci., 7, 319-329.
47. Hamilton-Dutoit, S. J., Pallesen, G., Karkov, J., Skinhoj, P., Franz-mann, M. B., and Pedersen, C. (1989). Identification of EBV-DNA in tumour cells of AIDS-related lymphomas by in-situ hybridisation. Lancet, 1, 554-562.
48. Hamilton-Dutoit, S. J., Pallesen, G., Franzmann, M. B. et al. (1991). Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am. J. Pathol., 138, 149-163.
49. Henderson, S., Rowe, M., Gregory, C. et al. (1991). Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infectedB cells from programmed cell death. Cell, 65, 1107-1115.
50. Hennessy, K. and Kieff, E. (1983). One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. Proc. Natl Acad. Sci. USA, 80, 5665-5669.
51. Hennessy, K., Heller, M., van Santen, V., and Kieff, E. (1983). Simple repeat array in Epstein-Barr virus DNA encodes part of the Epstein-Barr nuclear antigen. Science, 220, 1396-1398.
52. Hennessy, K., Fennewald, S., Hummel, M., Cole, T., and Kieff, E. (1984). A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc. Natl Acad. Sci. USA, 81, 7207-7211.
53. Hennessy, K., Fennewald, S., and Kieff, E. (1985). A third viral nuclear protein in lymphoblasts immortalized by Epstein-Barr virus. Proc. Natl Acad. Sci. USA, 82, 5944-5948.
54. Hickabottom, M., Parker, G. A., Freemont, P., Crook, T., and All-day, M. J. (2002). Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP). J. Biol. Chem., 277, 47197-47204.
55. Higuchi, M., Izumi, K. M., and Kieff, E. (2001). Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: Protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Proc. Natl Acad. Sci. USA, 98, 4675-4680.
56. Hsieh, J. J., Henkel, T., Salmon, P., Robey, E., Peterson, M. G., and Hayward, S. D. (1996). Truncated mammalian Notch1 acti-vates CBF1/RBPJk-repressed genes by a mechanism resem-bling that of Epstein-Barr virus EBNA2. Mol. Cell Biol., 16, 952-959.
57. Hu, L. F., Troyansky, B., Zhang, X. et al. (2000). Differences in the immunogenicity of latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus genomes derived from LMP1-positive and-negative nasopharyngeal carcinoma. Cancer Res., 60, 5589-5593.
58. Ikeda, M., Ikeda, A., Longan, L. C., and Longnecker, R. (2000). The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases. Virology, 268, 178-191.
59. Ikeda, M., Ikeda, A., Longnecker, R. (2002). Lysine-independent ubiquitination of Epstein-Barr virus LMP2A. Virology, 75, 153-159.
60. Ikeda, A., Caldwell, R. G., Longnecker, R., and Ikeda, M. (2003). Itchy, a Nedd4 ubiquitinligase, downregulateslatent membranepro-tein 2A activity in B-cell signaling. J. Virol., 77, 5529-5534.
61. Jiang, W. Q., Wendel-Hansen, V., Lundkvist, A., Ringertz, N., Klein, G., and Rosen, A. (1991). Intranuclear distribution of Epstein-Barr virus-encoded nuclear antigens EBNA-1,-2,-3 and-5. J. Cell Sci., 99, 497-502.
62. Jochner, N., Eick, D., Zimber-Strobl, U., Pawlita, M., Bornkamm, and Kempkes, B. (1996). EpsteinBarr virus nuclear anti-gen 2 is a transcriptional suppressor of the immunoglobulin mu gene: Implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells. EMBOJ., 15, 375-382.
63. Johannsen, E., Koh, E., Mosialos, G., Tong, X., Kieff, E., and Gross-man, S. R. (1995). Epstein-Barr virus nuclear protein 2 trans-activation of the latent membrane protein 1 promoter is medi-ated by J kappa and PU. 1. J. Virol., 69, 253-262.
64. Johannsen, E., Miller, C. L., Grossman, S. R., and Kieff, E. (1996). EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJ kappa in Epstein-Barr virus-transformed B lymphocytes. J. Virol., 70, 4179-4183.
65. Jones, C. H., Hayward, S. D., and Rawlins, D. R. (1989). Interaction of the lymphocyte-derived Epstein-Barr virus nuclear antigen EBNA-1 with its DNA-binding sites. J. Virol., 63, 101-110.
66. Kaiser, C., Laux, G., Eick, D., Jochner, N., Bornkamm, G. W., and Kempkes, B. (1999). The proto-oncogene c-myc is a direct tar-get gene of Epstein-Barr virus nuclear antigen 2. J. Virol., 73, 4481-4484.
67. Kanamori, M., Watanabe, S., Honma, R. et al. (2004). Epstein-Barr virus nuclear antigen leader protein induces expression of thymus-and activation-regulated chemokine in B cells. J. Virol., 78, 3984-3993.
68. Kashuba, E., Pokrovskaja, K., Klein, G., and Szekely, L. (1999). Epstein-Barr virus-encoded nuclear protein EBNA-3 interacts with the epsilon-subunit of the T-complex protein 1 chaper-onin complex. J. Hum. Virol., 2, 33-37.
69. Kashuba, E., Kashuba, V., Pokrovskaja, K., Klein, G., and Szekely, L. (2000). Epstein-Barr virus encoded nuclear protein EBNA-3 binds XAP-2, a protein associated with Hepatitis B virus X antigen. Oncogene, 19, 1801-1806.
70. Kashuba, E., Kashuba, V., Sandalova, T., Klein, G., and Szekely, L. (2002). Epstein-Barr virus encoded nuclear protein EBNA-3 binds a novel human uridine kinase/uracil phosphoribosyl-transferase. BMC Cell Biol., 3, 23.
71. Kashuba, E., Mattsson, K., Pokrovskaja, K. et al. (2003). EBV-encoded EBNA-5 associates with P14ARF in extranucleolar inclusions and prolongs the survival of P14ARF-expressing cells. Int. J. Cancer, 105, 644-653.
72. Kawanishi, M. (2000). The Epstein-Barr viruslatent membrane pro-tein 1 (LMP1) enhances TNF alpha-induced apoptosis of intes-tine 407 epithelial cells: The role of LMP1 C-terminal activation regions1 and 2. Virology, 270, 258-266.
73. Kaye, K. M., Izumi, K. M., Li, H. et al. (1999). An Epstein-Barr virus that expresses only the ?rst 231 LMP1 amino acids ef?-ciently initiates primary B-lymphocyte growth transforma-tion. J. Virol., 73, 10525-10530.
74. Kempkes, B., Pawlita, M., Zimber-Strobl, U., Eissner, G., Laux, G., and Bornkamm, G. W. (1995). Epstein-Barr virus nuclear anti-gen 2-estrogen receptor fusion protein transactivate viral and cellular genes and interact with RBP-J kappa a conditional fashion. Virology, 214, 675-679.
75. Kieser, A., Kilger, E., Gires, O., Uef?ng, M., Kolch, W., and Ham-merschmidt, W. (1997). Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J., 16, 6478-6485.
76. Kilger, E., Kieser, A., Baumann, M., and Hammerschmidt, W.(1998). Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J., 17, 1700-1709.
77. Kiss, C., Nishikawa, J., Takada, K., Trivedi, P., Klein, G., and Szekely, L. (2003). T cell leukemia 1 oncogene expression depends on the presence of Epstein-Barr virus in the virus-carrying Burkitt lymphoma lines. Proc. Natl Acad. Sci. USA, 100, 4813-4818.
78. Klein, G., Pearson, G., Rabson, A. et al. (1973). Antibody reactions to herpesvirus Saimiri (HVS)-induced early and late antigens (EA and LA) in HVS-infected squirrel, marmoset and owl monkeys. Int. J. Cancer, 12, 270-289.
79. Komano, J., Sugiura, M., and Takada, K. (1998). Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resis-tance in Burkitt's lymphoma cell line AKATA. J. Virol., 72, 9150-9156.
80. Krauer, K. G., Burgess, A., Buck, M., Flanagan, J., Sculley, T. B., and Gabrielli, B. (2004). The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene, 23, 1342-1353.
81. Kuppers, R., Schwering, I., Brauninger, A., Rajewsky, K., and Hansmann, M. L. (2002). Biology of Hodgkin's lymphoma. Ann. Oncol., 13 Suppl 1:11-18.
82. Lam, N., and Sugden, B. (2003). LMP1, a viral relative of the TNF receptor family, signals principally fromintracellular compart-ments. EMBO J., 22, 3027-3038.
83. Langerak, A. W., Moreau, E., van Gastel-Mol, E. I., van der Burg, M., and van Dongen, J. J. (2002) Detection of clonal EBV epi-somes in lymphoproliferations as a diagnostic tool. Leukemia, 16, 1572-1573.
84. Laux, G., Perricaudet, M., and Farrell, P. J. (1988). A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J., 7, 769-774.
85. Lee, B. S., Alvarez, X., Ishido, S., Lackner, A. A., and Jung, J. U. (2000). Inhibition of intracellular transport of B cell antigen recep-tor complexes by Kaposi's sarcoma-associated herpesvirus K1. J. Exp. Med., 192, 11-21.
86. Lennette, E. T., Winberg, G., Yadav, M., Enblad, G., and Klein, G. (1995). Antibodies to LMP2A/2B in EBV-carrying malignan-cies. Eur. J. Cancer, 31A, 1875-1878.
87. Levine, P. H., Pallesen, G., Ebbesen, P., Harris, N., Evans, A. S., and Mueller, N. (1994). Evaluation of Epstein-Barr virus anti-body patterns and detection of viral markers in the biopsies of patients with Hodgkin's disease. Int. J. Cancer, 5948-5950.
88. Levitskaya, J., Coram, M., Levitsky, V. et al. (1995). Inhibition of antigenprocessing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature, 375, 685-688.
89. Lin, J., Johannsen, E., Robertson, E., and Kieff, E. (2002). Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2. J. Virol., 76, 232-242.
90. Lindahl, T., Klein, G., Reedman, B. M., Johansson, B., and Singh, S. (1974). Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignan-cies. Int. J. Cancer, 13, 764-772.
91. Lo, K. W. and Huang, D. P. (2002). Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin. Cancer Biol., 12, 451-462.
92. Longnecker, R. and Kieff, E. (1990). A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J. Virol., 64, 2319-2326.
93. Lynch, D. T., Zimmerman, J. S., and Rowe, D. T. (2002). Epstein-Barr virus latent membrane protein 2B (LMP2B) co-localizes with LMP2A in perinuclear regions in transiently transfected cells. J. Gen. Virol., 83, 1025-1035.
94. Magrath, I. (1990). The pathogenesis of Burkitt's lymphoma, Adv. Cancer Res., 55, 133-269.
95. Matskova, L., Ernberg, I., Pawson, T., and Winberg, G. (2001). C-terminal domain of the Epstein-Barr virus LMP2a protein con-tains a clustering signal. J. Virol., 75, 10941-10949.
96. Mehl, A. M., Floettmann, J. E., Jones, M., Brennan, P., and Rowe, M. (2001). Characterization of intercellular adhesion molecule-1 regulation by Epstein-Barr virus-encoded latent membrane protein-1 identi?es pathways that cooperate with nuclear fac-tor kappa B to activate transcription. J. Biol. Chem., 276, 984-992.
97. Miller, C. L., Lee, J. H., Kieff, E., and Longnecker, R. (1994). An inte-gral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc. Natl Acad. Sci. USA, 91, 772-776.
98. Miyashita, E. M., Yang, B., Babcock, G. J., and Thorley-Lawson, D. A. (1997). Identification of the site of Epstein-Barr virus persis-tence in vivo as a resting B cell. J. Virol., 71, 4882-4891.
99. Molin, D., Fischer, M., Xiang, Z. et al. (2001). Mast cells express func-tional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br. J. Haematol., 114, 616-623.
100. Montalban, C., Abraira, V., Morente, M. et al. (2000). Epstein-Barr virus-latent membrane protein 1 expression has a favorable in?uence in the outcome of patients with Hodgkin's Disease treated with chemotherapy. Leuk. Lymphoma, 39, 563-572.
101. Morente, M. M., Piris, M. A., Abraira, V. et al. (1997). Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression. Blood, 90, 2429-2436.
102. Mosialos, G., Birkenbach, M., Yalamanchili, R., VanArsdale, T., Ware, C., and Kieff, E.(1995). The Epstein-Barr virustransform-ing protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell., 80, 389-399.
103. Murray, P. G., Billingham, L. J., Hassan, H. T., and Young, L. S. (1999). Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. Blood, 94, 442-447.
104. Muschen, M., Re, D., Brauninger, A. et al. (2000). Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells. Cancer Res., 60, 5640-5643.
105. Nicholas, J. (2003). Human herpesvirus-8-encoded signalling lig-ands and receptors. J. Biomed. Sci., 10, 475-489.
106. Niedobitek, G., Deacon, E. M., and Young, L. S. (1989). Epstein-Barr virus gene expression in Hodgkin's disease. Blood, 78, 1628-1630.
107. Nishikawa, J., Kiss, C., Imai, S. et al. (2003). Upregulation or the truncated basic hair keratin 1(hHb1-?N) in carcinoma cells by Epstein-Barr virus (EBV). Internat. J. Cancer, 107, 597-602.
108. Ohno, S., Luka, J., Lindahl, T., and Klein, G. (1977). Identification of a puri?ed complement-?xing antigen as the Epstein-Barr-virus determined nuclear antigen (EBNA) by its binding to metaphase chromosomes. Proc. Natl Acad. Sci. USA, 74, 1605-1609.
109. Ohshima, K., Suzumiya, J., Tasiro, K. et al. (1996). Epstein-Barr virus infection and associated products (LMP, EBNA2, vIL-10) in nodal non-Hodgkin's lymphomaof humanimmunode?ciency virus-negative Japanese. Am. J. Hematol., 52(1), 21-28.
110. Parker, G. A., Crook, T., Bain, M., Sara, E. A., Farrell, P. J., and Allday, M. J. (1996). Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to ade-novirus E1A and papillomavirus E7. Oncogene, 13, 2541-2549.
111. Parker, G. A., Touitou, R., and Allday, M. J. (2000). Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene, 19, 700-709.
112. Pathmanathan, R., Prasad, U., Sadler, R., Flynn, K., and Raab-Traub, N. (1995). Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal car-cinoma. N. Engl. J. Med., 333, 693-698.
113. Polack, A., Hortnagel, K., Pajic, A. et al. (1996). c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent mem-brane protein 1. Proc. Natl Acad. Sci. USA, 93, 10411-10416.
114. Polvino-Bodnar, M., Kiso, J., and Schaffer, P. A. (1988). Mutational analysisof Epstein-Barr virus nuclear antigen 1(EBNA 1). Nucl. Acids Res., 16, 3415-3435.
115. Pokrovskaja, K., Mattsson, K., Kashuba, E., Klein, G., and Szekely, L. (2001). Inhibitor induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5. J. Gen. Virol., 82, 345-358.
116. Prevot, S., Hamilton-Dutoit, S., Audouin, J., Walter, P., Pallesen, G., and Diebold, J. (1992). Analysis of African Burkitt's and high-grade B cell non-Burkitt's lymphoma for Epstein-Barr virus genomes using in situ hybridization. Br. J. Haematol, 80, 27-32.
117. Qu, L. and Rowe, D. T. (1992). Epstein-Barr virus latent gene expres-sion in uncultured peripheral blood lymphocytes. J. Virol., 66, 3715-3724.
118. Radkov, S. A., Bain, M., Farrell, P. J., West, M., Rowe, M., and All-day, M. J. (1997). Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J. Virol., 71, 8552-8562.
119. Radkov, S. A., Touitou, R., Brehm, A. et al. (1999). Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J. Virol., 73, 5688-5697.
120. Radkov, S., Kellam, P., and Boshoff, C. (2000). The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat. Med., 6, 1121-1127.
121. Rawlins, D. R., Milman, G., Hayward, S. D., and Hayward, G. S. (1985). Sequence-speci?c DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plas-mid maintenance region. Cell, 42, 859-868.
122. Rea, D., Fourcade, C., Leblond, V. et al. (1994). Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation, 58, 317-324.
123. Reedman, B. M. and Klein, G. (1973). Related Articles, Cellu-lar localization of an Epstein-Barr virus (EBV)-associated complement-?xing antigen in producer and non-producer lymphoblastoid cell lines. Int. J. Cancer, 11, 499-520.
124. Reisman, D. and Sugden, B. (1986). Trans-activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol. Cell Biol., 6, 3838-3846.
125. Rickinson, A. B., Young, L. S., and Rowe, M. (1987). In?uence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phe-notype of virus-transformedB cells. J. Virol., 61, 1310-1317.
126. Rous, P. (1911). A sarcoma of fowl transmissible by an agent from the tumor cells. J. Exp. Med., 13, 397-411.
127. Rowe, M., Young, L. S., Cadwallader, K., Petti, L., Kieff, E., and Rickin-son, A. B.(1989). Distinctionbetween Epstein-Barr virustype A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J. Virol., 63, 1031-1039.
128. Rowe, M., Khanna, R., Jacob, C. A. et al. (1995). Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: Coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur. J. Immunol., 25, 1374-1384.
129. Scholle, F., Bendt, K. M., and Raab-Traub, N. (2000). Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differen-tiation, and activates Akt. J. Virol., 74, 10681-10689.
130. Sample, J. and Kieff, E. (1990). Transcription of the Epstein-Barr virus genome during latency in growth-transformed lympho-cytes. J. Virol., 64, 1667-1674.
131. Shimizu, N., Yamaki, M., Sakuma, S., Ono, Y., and Takada, K. (1988). Three Epstein-Barr virus (EBV)-determined nuclear antigens induced by the BamHI E region of EBV DNA. Int. J. Cancer, 41, 744-751.
132. Shope, R. E. (1933). Infectious papillomatosis of rabbits; with a note on the histopathology. J. Exp. Med., 68, 607-624.
133. Spieker, T., Kurth, J., Kuppers, R., Rajewsky, K., Brauninger, A., and Hansmann, M. L. (2000). Molecular single-cell analy-sis of the clonal relationship of small Epstein-Barr virus-infected cells and Epstein-Barr virus-harboring Hodgkin and Reed/Sternberg cells in Hodgkin disease. Blood., 96, 3133-3138.
134. Sugden, B. and Warren, N. (1989). A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J. Virol., 63, 2644-2649.
135. Swart, R., Ruf, I. K., Sample, J., and Longnecker, R. (2000). Latent membrane protein 2A-mediated effects on the phosphatidyli-nositol 3-kinase/Akt pathway. J. Virol., 74, 10838-10845.
136. Takada, K. (2001). Role of Epstein-Barr virus in Burkitt's lymphoma. Curr. Top. Microbiol. Immunol., 258, 141-161.
137. Tamura, K., Taniguchi, Y., Minoguchi, S. et al. (1995). Physical interaction between a novel domain of the receptor Notch and the transcription factor RBP-Jk. Curr. Biol., 5, 1416-1423.
138. Tan, L. C., Gudgeon, N., Annels, N. et al. (1999). Re-evaluation of the frequency of CD8+ T cells speci?c for EBV in healthy virus carriers. J. Immunol., 162, 1827-1835.
139. Tepper, C. and Seldin, M. (1999). Modulation of Casoase-8 and FLICE-inhibitory proytein expression as a potential mech-anism of Epstein-Barr virus tumorigeneis in Burkitt's lym-phoma. Blood, 94, 1727-1737.
140. Tierney, R. J., Steven, N., Young, L. S., and Rickinson, A. B. (1994). Epstein-Barr virus latency in blood mononuclear cells: Analy-sis of viral gene transcription during primary infection and in the carrier state. J. Virol., 68, 7374-7385.
141. Touitou, R., Hickabottom, M., Parker, G., Crook, T., and Allday, M. J. (2001). Physical and functional interactions between the corepressor CtBP and the Epstein-Barr virus nuclear antigen EBNA3C. J. Virol., 75, 7749-7755.
142. Verschueren, E. W., Klefstrom, J., Evan, G. I., and Jones, N. (2002). The oncogeneic potential of Kaposi's sarcoma-associated her-pesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell, 2, 229-241.
143. Wang, F., Gregory, C. D., Rowe, M. et al. (1987a). Epstein-Barr virus nuclear antigen 2 speci?cally induces expression of the B-cell activation antigen CD23. Proc. Natl Acad. Sci. USA, 84, 3452-3456.
144. Wang, F., Petti, L., Braun, D., Seung, S., and Kieff, E. (1987b). Free in PMC A bicistronic Epstein-Barr virus mRNA encodes two nuclear proteins in latently infected, growth-transformed lym-phocytes. J. Virol., 61, 945-954.
145. Wang, F., Gregory, C., Sample, C. et al. (1990). Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol., 64, 2309-2318.
146. Webster-Cyriaque, J. and Raab-Traub, N. (1998). Transcription of Epstein-Barr virus latent cycle genes in oral hairy leukoplakia. Virology, 248, 53-65.
147. Weng, A. P., Shahsafaei, A., and Dorfman, D. M. (2003). CXCR4/CD184 immunoreactivity in T-cell non-Hodgkin lym-phomas with an overall Th1-Th2+ immunophenotype. Am. J.
148. West, M. J., Webb, H. M., Sinclair, A. J., and Woolfson DN. (2004). Biophysical and mutational analysis of the putative bZIP domain of Epstein-Barr virus EBNA 3C. J. Virol., 78, 9431-9445.
149. Winberg, G., Matskova, L., Chen, F. et al. (2000). Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 protein-ubiquitin ligases that ubiquitinate B-cell tyrosine kinases. Mol. Cell, 20, 8526-8535.
150. Zhang, X., Hu, L., Fadeel, B., and Ernberg, I. T. (2002). Apoptosis modulation of Epstein-Barr virus-encoded latent membrane protein 1 in the epithelial cell line HeLa is stimulus-dependent. Virology, 304, 330-341.
151. Zhao, B., Dalbies-Tran, R., Jiang, H. etal. (2003). Transcriptional reg-ulatory properties of Epstein-Barr virus nuclear antigen 3C are conserved in simian lymphocryptoviruses. J. Virol., 77, 5639-5648.
152. Zimber, U., Adldinger, H. K., Lenoir, G.M. etal.(1986). Geographical prevalence of two types of Epstein-Barr virus. Virology, 154, 56-66.
153. Zimber-Strobl, U., Kempkes, B., Marschall, G. et al. (1996). Epstein-Barr virus latent membrane protein (LMP1) is not suf?cient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J., 15, 7070-7078.
154. Zhou, X. G., Hamilton-Dutoit, S. J., Yan, Q. H., and Pallesen, G. (1994). High frequency of Epstein-Barr virus in Chinese peripheral T-cell lymphoma. Histopathology, 24, 115-122.